Macrogenics
Clinical trials sponsored by Macrogenics, explained in plain language.
-
New drug combo aims to slow advanced prostate cancer
Disease control CompletedThis study tests whether adding an immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with a tough-to-treat type of prostate cancer live longer without their disease getting worse. About 150 men with metastatic castration-resistant prostate c…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC